Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT06416969
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Somatostatin — DRUG
    Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
  • Epinephrine — DRUG
    Intravenous infusion

Study Details

Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.

Key Dates

Start date
Jan 1, 2024
Status verified
May 2026
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Obesity Group
    Subjects that have upper body obesity will receive somatostatin plus epinephrine
  • Experimental: Lean Group
    Subject wo are normal weight will receive somatostatin plus epinephrine

Primary Outcome Measure

Free Fatty Acid (FFA) release from femoral, splanchnic and upper body subcutaneous adipose tissue [ Time Frame: approximately 3.5 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Madeline Reid
[email protected]
507-255-6062
Kelli A Lytle, PhD
[email protected]
(507) 255-1488

Find similar trials in Rochester, MN

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies